JP2014532620A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014532620A5 JP2014532620A5 JP2014536398A JP2014536398A JP2014532620A5 JP 2014532620 A5 JP2014532620 A5 JP 2014532620A5 JP 2014536398 A JP2014536398 A JP 2014536398A JP 2014536398 A JP2014536398 A JP 2014536398A JP 2014532620 A5 JP2014532620 A5 JP 2014532620A5
- Authority
- JP
- Japan
- Prior art keywords
- influenza
- virus
- immunogenic composition
- motomeko
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 claims description 55
- 230000002163 immunogen Effects 0.000 claims description 52
- 241000713196 Influenza B virus Species 0.000 claims description 34
- 239000000427 antigen Substances 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 239000002671 adjuvant Substances 0.000 claims description 14
- 239000007764 o/w emulsion Substances 0.000 claims description 9
- 230000003053 immunization Effects 0.000 claims description 8
- 241000712431 Influenza A virus Species 0.000 claims description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 2
- 206010069767 H1N1 influenza Diseases 0.000 claims description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 229960003971 influenza vaccine Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229940031439 squalene Drugs 0.000 claims description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 2
- 201000010740 swine influenza Diseases 0.000 claims description 2
- 230000005847 immunogenicity Effects 0.000 claims 2
- 208000037798 influenza B Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 18
- 229960005486 vaccine Drugs 0.000 description 2
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161627995P | 2011-10-20 | 2011-10-20 | |
| US61/627,995 | 2011-10-20 | ||
| PCT/IB2012/055751 WO2013057715A1 (en) | 2011-10-20 | 2012-10-19 | Adjuvanted influenza b virus vaccines for pediatric priming |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014532620A JP2014532620A (ja) | 2014-12-08 |
| JP2014532620A5 true JP2014532620A5 (https=) | 2015-12-03 |
Family
ID=47297335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014536398A Ceased JP2014532620A (ja) | 2011-10-20 | 2012-10-19 | 小児の初回免疫のためのアジュバント添加インフルエンザｂウイルスワクチン |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20140248320A1 (https=) |
| EP (1) | EP2768528A1 (https=) |
| JP (1) | JP2014532620A (https=) |
| AU (1) | AU2012324398A1 (https=) |
| CA (1) | CA2852857A1 (https=) |
| WO (1) | WO2013057715A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101674904B1 (ko) | 2009-02-26 | 2016-11-10 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 중재형 약물전달 시스템과 그 방법 |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| KR101370512B1 (ko) * | 2013-06-07 | 2014-03-06 | 재단법인 목암생명공학연구소 | 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법 |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| US10872313B2 (en) | 2015-06-02 | 2020-12-22 | ROCA Medical Ltd. | Method for repurposing NDC codes in a pharmaceutical database for venom derived allergens involved in venom immunotherapy |
| PL4023249T3 (pl) | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| US10548974B2 (en) * | 2015-06-02 | 2020-02-04 | ROCA Medical Ltd. | Therapeutic treatment kit for allergies based on DNA profiles |
| JP6948313B6 (ja) | 2015-09-17 | 2022-01-14 | モデルナティエックス インコーポレイテッド | 治療剤の細胞内送達のための化合物および組成物 |
| PL3386484T3 (pl) | 2015-12-10 | 2022-07-25 | Modernatx, Inc. | Kompozycje i sposoby dostarczania środków terapeutycznych |
| LT3394030T (lt) | 2015-12-22 | 2022-04-11 | Modernatx, Inc. | Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| EP4186888B1 (en) | 2017-03-15 | 2025-11-26 | ModernaTX, Inc. | Compound and compositions for intracellular delivery of therapeutic agents |
| WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| EP3675817A1 (en) | 2017-08-31 | 2020-07-08 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| ES2991988T3 (es) | 2017-10-30 | 2024-12-05 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica |
| WO2020061295A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| WO2020061367A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| CA3113025A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| AU2020350759A1 (en) | 2019-09-19 | 2022-03-31 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| CA3155015A1 (en) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4060082A (en) | 1976-08-16 | 1977-11-29 | Mpl, Inc. | Dual-ingredient medication dispenser |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| JPH0614756Y2 (ja) | 1991-06-26 | 1994-04-20 | 株式会社アルテ | 組み立て式の２室式容器兼用注射器 |
| US5762939A (en) | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
| WO1995011700A1 (en) | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| US5496284A (en) | 1994-09-27 | 1996-03-05 | Waldenburg; Ottfried | Dual-chamber syringe & method |
| DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
| AU3186297A (en) | 1996-07-05 | 1998-02-02 | Debiotech S.A. | Dual-chamber syringe for mixing two substances prior to injection |
| TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| WO1998046262A1 (en) | 1997-04-16 | 1998-10-22 | Connaught Laboratories, Inc. | Anti-influenza compositions supplemented with neuraminidase |
| US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| WO1999017820A1 (en) | 1997-10-03 | 1999-04-15 | Texas Pharmaceuticals, Inc. | Improved dual chamber syringe apparatus |
| US5971953A (en) | 1998-01-09 | 1999-10-26 | Bachynsky; Nicholas | Dual chamber syringe apparatus |
| NZ508013A (en) | 1998-05-07 | 2003-08-29 | Corixa Corp | Adjuvant composition for use with an antigen in a vaccine composition |
| DE19835749C1 (de) | 1998-08-07 | 2000-02-03 | Dieter Perthes | Fertig-Spritze für nicht-stabile Arzneimittel |
| US6544785B1 (en) | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
| DE122008000035I1 (de) | 1999-04-06 | 2009-05-20 | Wisconsin Alumni Res Found | Rekombinante influenzaviren zur vakzinherstellung und gentherapie |
| ES2278621T5 (es) | 1999-07-14 | 2011-02-02 | Mount Sinai School Of Medicine Of New York University | Reconstrucción in vitro de virus arn segmentados de polaridad negativa. |
| KR100797547B1 (ko) | 2000-03-03 | 2008-01-24 | 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 | 무혈청 배양 및 부유 배양에서 사용할 수 있는 세포 및상기 세포를 사용하여 백신용 바이러스를 제조하는 방법 |
| ES2319864T3 (es) | 2000-04-28 | 2009-05-14 | St. Jude Children's Research Hospital | Sistema de transfeccion de adn para la generacion de virus infecciosos de arn de cadena negativa. |
| FR2808803B1 (fr) | 2000-05-11 | 2004-12-10 | Agronomique Inst Nat Rech | Cellules es modifiees et gene specifique de cellules es |
| GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
| CA2438960A1 (en) | 2001-02-23 | 2002-09-06 | Glaxosmithkline Biologicals S.A. | Influenza vaccine formulations for intradermal delivery |
| EP2281573A3 (en) | 2001-02-23 | 2011-12-07 | GlaxoSmithKline Biologicals s.a. | Influenza vaccine formulations for intradermal delivery |
| MY134424A (en) | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
| FR2832423B1 (fr) | 2001-11-22 | 2004-10-08 | Vivalis | Systeme d'expression de proteines exogenes dans un systeme aviaire |
| FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| KR101153898B1 (ko) | 2004-03-23 | 2012-06-18 | 니프로 가부시키가이샤 | 프리필드 시린지 |
| KR20110132416A (ko) | 2004-04-05 | 2011-12-07 | 화이자 프로덕츠 인코포레이티드 | 미세유체화된 수중유 유화액 및 백신 조성물 |
| WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
| JP2007537760A (ja) | 2004-05-20 | 2007-12-27 | アイディー バイオメディカル コーポレイション | インフルエンザワクチンを製造するためのプロセス |
| ATE489965T1 (de) | 2004-09-09 | 2010-12-15 | Novartis Vaccines & Diagnostic | Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen |
| DK2368975T3 (en) | 2004-12-23 | 2015-01-05 | Medimmune Llc | Non-tumorigenic MDCK cell line for the propagation of viruses |
| EP2295542B1 (en) | 2004-12-24 | 2013-01-30 | Abbott Biologicals B.V. | Rescue of influenza virus |
| FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
| US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
| US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
| FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| PL2478916T3 (pl) | 2006-01-27 | 2020-11-16 | Seqirus UK Limited | Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy |
| EA015817B1 (ru) | 2006-10-12 | 2011-12-30 | Глаксосмитклайн Байолоджикалс С.А. | Иммуногенная композиция, содержащая адъювант в виде эмульсии "масло в воде" |
| PT2121011E (pt) * | 2006-12-06 | 2014-07-31 | Novartis Ag | Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe |
| PE20090146A1 (es) * | 2007-04-20 | 2009-03-23 | Glaxosmithkline Biolog Sa | Composicion inmunogenica contra el virus influenza |
| JP2011506290A (ja) * | 2007-12-06 | 2011-03-03 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | インフルエンザ組成物 |
| US8506966B2 (en) * | 2008-02-22 | 2013-08-13 | Novartis Ag | Adjuvanted influenza vaccines for pediatric use |
| WO2010129947A2 (en) * | 2009-05-08 | 2010-11-11 | Sciclone Pharmaceuticals, Inc. | Alpha thymosin peptides as vaccine enhancers |
-
2012
- 2012-10-19 EP EP12797981.3A patent/EP2768528A1/en not_active Withdrawn
- 2012-10-19 CA CA2852857A patent/CA2852857A1/en not_active Abandoned
- 2012-10-19 AU AU2012324398A patent/AU2012324398A1/en not_active Abandoned
- 2012-10-19 WO PCT/IB2012/055751 patent/WO2013057715A1/en not_active Ceased
- 2012-10-19 US US14/352,955 patent/US20140248320A1/en not_active Abandoned
- 2012-10-19 JP JP2014536398A patent/JP2014532620A/ja not_active Ceased
-
2018
- 2018-11-16 US US16/193,024 patent/US20190247489A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014532620A5 (https=) | ||
| Shah et al. | Overview of vaccine adjuvants: introduction, history, and current status | |
| Peek et al. | Nanotechnology in vaccine delivery | |
| JP2011504486A5 (https=) | ||
| JP2016185988A5 (https=) | ||
| Wilschut | Influenza vaccines: the virosome concept | |
| TW200722101A (en) | Novel composition | |
| JP2009539965A5 (https=) | ||
| Banzhoff et al. | MF59®‐adjuvanted vaccines for seasonal and pandemic influenza prophylaxis | |
| Haddadin et al. | Alternative strategies of posttransplant influenza vaccination in adult solid organ transplant recipients | |
| Atmar et al. | Adjuvants for pandemic influenza vaccines | |
| JP2016506416A5 (https=) | ||
| Dehghan et al. | Rabbit nasal immunization against influenza by dry-powder form of chitosan nanospheres encapsulated with influenza whole virus and adjuvants | |
| EA200900024A1 (ru) | Противогриппозная вакцина | |
| NZ594482A (en) | Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant | |
| Parodi et al. | Inactivated influenza vaccines: recent progress and implications for the elderly | |
| Cibulski et al. | Zika virus envelope domain III recombinant protein delivered with saponin-based nanoadjuvant from Quillaja brasiliensis enhances anti-Zika immune responses, including neutralizing antibodies and splenocyte proliferation | |
| Romeli et al. | Multi-epitope peptide-based and vaccinia-based universal influenza vaccine candidates subjected to clinical trials | |
| Jang et al. | Cross-protective immune responses elicited by live attenuated influenza vaccines | |
| RU2017137357A (ru) | Быстрорастворяющаяся лекарственная форма пероральной вакцины, в которой используют крахмал | |
| JP2016508999A5 (https=) | ||
| Rambe et al. | Safety and mechanism of action of licensed vaccine adjuvants | |
| JP2009514839A5 (https=) | ||
| EP2310045A1 (en) | Rapid responses to delayed booster immunisations | |
| JP2011525902A5 (https=) |